Metformin Registry Study - EDMARC

Go to content
Metformin, as a possible reproductive toxicant, and the risk of birth defects and other adverse birth outcomes in women taking metformin
March 1, 2022 - February 28, 2025

A National Registry Project linking several registries in order to study the impact of maternal metformin exposure during pregnancy on several adverse pregnancy outcomes and congenital malformations in the offspring. The project is expected to give insight into underlying factors for decreasing reproductive health.
An article describing background and hypothesis behind the study has recently been published: Tavlo et al., Frontiers of Endocrinology, 2022.

The Research Team
The project has been developed in close collaboration between Rigshospitalet, including  the EDMARC group (prof. Anders Juul, prof. Niels Erik Skakkebæk and Dr. Anna-Maria Andersson) and  Centre for Pregnant Women with Diabetes, Department of Endocrinology, Rigshospitalet (prof. Elisabeth Mathiesen), and Department of Biology, University of Copenhagen (ass. prof. David M. Kristensen) and Department of Epidemiology, Biostatistics, and Biodemography, Department of Public Health, University of Southern Denmark  (prof. Rune Lindahl-Jacobsen and ass. prof. Silvia Rizzi).
Funding for a ph.d. student at SDU (Maja Tavlo) was obtained through a grant from Ferring to EDMARC and Globe Institute, University of Copenhagen (Eske Willerslev, Kurt Kjær, and Anders Juul, Niels E. Skakkebæk, Rune Jacobsen)

Project contact person at EDMaRC:
Niels Erik Skakkebæk
MDSci, Professor

Dept. of Growth and Reproduction
Copenhagen University Hospital, Rigshospitalet
Blegdamsvej 9
DK-2100 Copenhagen Denmark

Back to content